
Innovent Presents Updated Results from Phase 2 Study of Dupert Fulzerasib in Advanced Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Innovent Biologics Presents Updated Results of Dupert® in NSCLC Patients at WCLC 2024 SAN FRANCISCO and SUZHOU, China, Sept. 9, 2024 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a leading biopharmaceutical company specializing in the development and commercialization of high-quality medicines, has announced the presentation of new data from a Phase 2 clinical trial…